Navigation Links
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/26/2008

fic T-cell responses. These findings verify the company's predicted mechanism-of-action of HspE7 as demonstrated by early preclinical models and support the compound's potential to treat HPV-16 induced CIN. HPV-16 is the most common subtype of the HPV virus and is responsible for a significant percentage of cases of CIN.

"We are very encouraged with the interim immunological results from our Phase 1 HspE7 trial as they demonstrate the anticipated immune response improvement from cohort 1 to cohort 2. We believe that these results may correlate to the activity of the drug in future clinical trials," said Gregory M. McKee, president and chief executive officer at Nventa. "We look forward to reviewing the immunological data from the remaining two cohorts of this study to determine if yet higher doses of HspE7 will improve the drug's immunological activity."

The company recently announced positive safety and tolerability findings from cohort 3 in this Phase 1 study, as well as the completion of enrollment and initiation of dosing for the study's fourth and final cohort. Safety and tolerability results from cohort 4 are expected in mid-April. In addition to safety findings, immunological samples for the study's third and fourth cohorts are presently being collected and evaluated, and such findings will be released in the next several months.

Nventa is currently working with the FDA to finalize trial design for the company's Phase 2 clinical study for HspE7, and expects to initiate this trial in patients in CIN in mid-2008. In addition to CIN, Nventa is currently evaluating HspE7 as a potential treatment for a broad range of HPV-related pre-cancerous and cancerous diseases, and has a platform to generate other compounds that may treat a variety of other viral associated diseases.

About Cervical Intraepithelial Neoplasia (CIN)

CIN, also known as cervical dysplasia, is characterized by the presence in the cervix of abnormal cells that prec
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
6. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
7. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
8. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Chiasma, Inc. (NASDAQ: CHMA ), ... for the orphan condition acromegaly, today reported financial ... 2015 and provided a corporate update. ... time for Chiasma, as we successfully completed our ... first New Drug Application (NDA) has been accepted ...
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... Aug. 31, 2015  The departments of Drug and ... at Gaudenzia Concept 90 to raise awareness for International ... in Pennsylvania and help more ... on recovery through the Building Bridges to Recovery ... dying every day to a disease that is fully ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Identify Unique microRNA Signatures That Will ... Project Will Leverage Rosetta Genomics, Proprietary microRNA Extraction, and Quantification Technologies, ... and Experience ... Patients With High Risk, of Recurrence, who may Benefit From Adjuvant ...
... Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for ... ... Neuropathy, SAN FRANCISCO, June 6 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... trial (SB-509-701) in subjects with moderate to,severe diabetic neuropathy. Additionally, based upon ...
Cached Medicine Technology:Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 2Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 3Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 4Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 5Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 2Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 3Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 4Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 5
(Date:9/1/2015)... ... September 01, 2015 , ... Routines… every family has them. Whether ... make things easier for parents, caregivers and children too. Here are three reasons why ... and small become more fluid. When a routine is implemented into a child’s schedule, ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and ... and stickers to keep little ones' safety top of mind at all times. , ... particular focus. According to the JPMA's Baby Safety Zone website, this year's theme is ...
(Date:9/1/2015)... ... 2015 , ... Curly Hair Solutions™ is thrilled to partner ... partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution of ... Curly Hair Solutions™ team could not be more delighted to see their line ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... chronic back pain – once required a long, arduous recovery. However, today’s minimally ... less pain, less blood loss and minimal muscle damage. These advantages of minimally ...
(Date:8/31/2015)... ... 31, 2015 , ... Cosmetic Town Journal is an online ... have a successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients ... ready to help. , It is clear that the Cosmetic Town aesthetic surgery ...
Breaking Medicine News(10 mins):Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2
... Va.With the most recent release of data from the ... the moment of critical mass by confirming the effectiveness ... tumor activity across a wide range of cancers. , ... that PET finds more areas of active cancer than ...
... is the driving force for a safe return to the ... Dec. 1 /PRNewswire-USNewswire/ - - While many patients recovering ... to get back into their old routines, knowing when it,s ... be a difficult and complex decision to make. A discussion ...
... 1 Sciton introduces ProLipo,PLUS(TM), an FDA-cleared, minimally ... unwanted fat, resulting in collagen remodeling and,tissue tightening. ... nm wavelengths in,one laser for optimal body sculpting ... liposuction, it can also be utilized as a ...
... of Cumbria found that nine in every ten youngsters want to ... the boredom of,exercise. , Fifty ... with video games provided by a company called Gamercize. , ... only while they maintained movement on,the fitness machines. If they stopped ...
... What do poetry, art, literature,film and history have to ... M.D., Chair of Medicine at Saint Barnabas Medical Center,who ... bedside for,residents in internal medicine. , ... the ,soul, of medicine,",explains Dr. Panush, who is a ...
... Expand Company,s Specialty Offerings- , , ... , WORCESTER, Mass., Dec. 1 The Hanover Insurance ... property and casualty company, announced today that it has completed the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20051031/NEM023LOGO ) , ...
Cached Medicine News:Health News:Nationwide study confirms PET as the most powerful imaging tool in cancer management 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 3Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:Children Tell Researchers: We'll Get Fit if It's Fun 2Health News:Saint Barnabas Medical Center Pioneers New Program Bringing Humanities and Humanism to Medicine 2Health News:Saint Barnabas Medical Center Pioneers New Program Bringing Humanities and Humanism to Medicine 3Health News:Saint Barnabas Medical Center Pioneers New Program Bringing Humanities and Humanism to Medicine 4Health News:The Hanover Insurance Group Completes Acquisition of AIX Holdings, Inc. 2Health News:The Hanover Insurance Group Completes Acquisition of AIX Holdings, Inc. 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: